EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Real-world data on the use of subcutaneous daratumumab plus bortezomib, thalidomide, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

Vania Hungria, Fernanda Lemos Moura, Abel Costa, Eduardo Flávio Oliveira Ribeiro, Paulo Soares, Juliana Souza Lima, Lisa Aquaroni Ricci, Celso Arrais-Rodrigues, Fabio Moore Nucci, Marinus de Moraes Lima, Roberto Jose Pessoa de Magalhães Filho, Amitabha Bhaumik und 5 weitere

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06365-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, 2025. Verfasst von Vania Hungria und 16 weiteren Autor:innen. Beteiligte Einrichtung: Clinica São Germano, Rua Comendador Miguel Calfat 165, São Paulo, SP, 04537-080, Brazil. hungria@dialdata.com.br. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Subcutaneous daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd), is approved for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). However, additional real-world data are needed to assess the effectiveness and safety of D-VTd in routine clinical practice. We conducted a noninterventional, multicenter, observational study across hematology centers in Brazil to gather real-world data on D-VTd in patients with NDMM who were eligible for autologous stem cell transplant (ASCT). Eligible patients must have completed 1 or more cycle of D-VTd, on or before September 30, 2022, to be included. Data were collected retrospectively from the start of D-VTd to the study inclusion visit using patient medical records and prospectively thereafter using electronic case report forms. As of the data cutoff (August 8, 2023), 49 patients were included. By the end of consolidation, 91.7% of patients achieved an overall response (partial response or better) and 89.6% achieved very good partial response or better. Forty-five (91.8%) patients underwent stem cell mobilization with a median stem cell yield of 5.7 × 10 6 CD34+ cells/kg, and 44 (89.8%) patients underwent ASCT, among whom 43 out of 44 (97.7%) successfully completed ASCT. D-VTd was well tolerated, with a safety profile consistent with that previously known for daratumumab and VTd. Grade 3/4 neutropenia/febrile neutropenia and infections were reported in 32.7% and 18.4% of patients, respectively. Overall, results were consistent with the established profile of D-VTd, and these real-world effectiveness and safety results support the frontline use of subcutaneous daratumumab plus VTd in transplant-eligible patients with NDMM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsAntibodies, MonoclonalHematopoietic Stem Cell TransplantationHumansDexamethasoneBortezomibFemaleMiddle AgedMaleThalidomideAgedAdultRetrospective StudiesInjections, Subcutaneous

Stichwörter der Autor:innen

Autologous stem cell transplantDaratumumabMultiple myelomaReal-worldSubcutaneous

Substanzen

daratumumabDexamethasoneBortezomibThalidomideAntibodies, Monoclonal

Autor:innen und Institutionen

  • Clinica São Germano, Rua Comendador Miguel Calfat 165, São Paulo, SP, 04537-080, Brazil. hungria@dialdata.com.br.
  • Fundação Antonio Prudente - AC Camargo Cancer Center, São Paulo, SP, Brazil.
  • Instituto D'Or de Pesquisa e Ensino, São Paulo, SP, Brazil.
  • Hospital Santa Lúcia, Brasilia, Distrito Federal, Brazil.
  • Instituto D'Or de Pesquisa e Ensino, Brasilia, Distrito Federal, PE, Brazil.
  • Instituto de Hematologia e Oncologia Curitiba, Curitiba, PR, Brazil.

Förderung

  • Johnson & Johnson

Zitieren

APA

Hungria, V., Moura, F. L., Costa, A., Ribeiro, E. F. O., Soares, P., Lima, J. S., Ricci, L. A., Arrais-Rodrigues, C., Nucci, F. M., de Moraes Lima, M., de Magalhães Filho, R. J. P., Bhaumik, A., Parekh, T., Borgsten, F., Carson, R., Trufelli, D. C., & de Queiroz Crusoe, E. (2025). Real-world data on the use of subcutaneous daratumumab plus bortezomib, thalidomide, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Annals of Hematology. https://doi.org/10.1007/s00277-025-06365-3

Vancouver

Hungria V, Moura FL, Costa A, Ribeiro EFO, Soares P, Lima JS, et al. Real-world data on the use of subcutaneous daratumumab plus bortezomib, thalidomide, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Annals of Hematology. 2025. doi:10.1007/s00277-025-06365-3

BibTeX
@article{Hungria2025,
  author = {Hungria, Vania and Moura, Fernanda Lemos and Costa, Abel and Ribeiro, Eduardo Flávio Oliveira and Soares, Paulo and Lima, Juliana Souza and Ricci, Lisa Aquaroni and Arrais-Rodrigues, Celso and Nucci, Fabio Moore and de Moraes Lima, Marinus and de Magalhães Filho, Roberto Jose Pessoa and Bhaumik, Amitabha and Parekh, Trilok and Borgsten, Fredrik and Carson, Robin and Trufelli, Damila C and de Queiroz Crusoe, Edvan},
  title = {Real-world data on the use of subcutaneous daratumumab plus bortezomib, thalidomide, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06365-3}
}
Kostenlos starten →